Arcutis Biotherapeutics, Inc. (ARQT)
ARQT Stock Price Chart
Explore Arcutis Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ARQT price movements and trends.
ARQT Company Profile
Discover essential business fundamentals and corporate details for Arcutis Biotherapeutics, Inc. (ARQT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2020
Employees
342.00
Website
https://www.arcutis.comCEO
Todd Franklin Watanabe
Description
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
ARQT Financial Timeline
Browse a chronological timeline of Arcutis Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.07, while revenue estimate is $118.47m.
Earnings released on 6 May 2026
EPS came in at -$0.09 falling short of the estimated -$0.02 by -350.00%, while revenue for the quarter reached $105.40m , beating expectations by +1.66%.
Earnings released on 25 Feb 2026
EPS came in at $0.13 surpassing the estimated $0.03 by +333.33%, while revenue for the quarter reached $129.50m , beating expectations by +14.55%.
Earnings released on 28 Oct 2025
EPS came in at $0.06 surpassing the estimated -$0.10 by +160.00%, while revenue for the quarter reached $99.22m , missing expectations by -10.45%.
Earnings released on 6 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $81.50m , beating expectations by +1.09%.
Earnings released on 6 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%, while revenue for the quarter reached $65.85m , missing expectations by -9.43%.
Earnings released on 25 Feb 2025
EPS came in at -$0.09 surpassing the estimated -$0.28 by +67.86%, while revenue for the quarter reached $71.36m , beating expectations by +17.92%.
Earnings released on 6 Nov 2024
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $44.76m , beating expectations by +18.97%.
Earnings released on 14 Aug 2024
EPS came in at -$0.42 surpassing the estimated -$0.48 by +12.50%, while revenue for the quarter reached $30.86m , beating expectations by +6.11%.
Earnings released on 14 May 2024
EPS came in at -$0.32 surpassing the estimated -$0.60 by +46.67%, while revenue for the quarter reached $49.57m , beating expectations by +236.29%.
Earnings released on 27 Feb 2024
EPS came in at -$0.72 falling short of the estimated -$0.65 by -10.77%, while revenue for the quarter reached $13.53m , beating expectations by +19.28%.
Earnings released on 3 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.90 by +18.89%, while revenue for the quarter reached $38.11m , beating expectations by +229.38%.
Earnings released on 8 Aug 2023
EPS came in at -$1.16 surpassing the estimated -$1.22 by +4.92%, while revenue for the quarter reached $5.19m , beating expectations by +12.83%.
Earnings released on 9 May 2023
EPS came in at -$1.31 falling short of the estimated -$1.30 by -0.77%, while revenue for the quarter reached $2.78m , missing expectations by -11.43%.
Earnings released on 28 Feb 2023
EPS came in at -$1.18 surpassing the estimated -$1.37 by +13.87%, while revenue for the quarter reached $2.96m , beating expectations by +34.44%.
Earnings released on 8 Nov 2022
EPS came in at -$1.89 falling short of the estimated -$1.54 by -22.73%, while revenue for the quarter reached $725.00k , beating expectations by +18.02%.
Earnings released on 4 Aug 2022
EPS came in at -$1.31 surpassing the estimated -$1.38 by +5.07%.
Earnings released on 5 May 2022
EPS came in at -$1.27 surpassing the estimated -$1.42 by +10.56%.
Earnings released on 22 Feb 2022
EPS came in at -$1.42 falling short of the estimated -$1.41 by -0.71%.
Earnings released on 4 Nov 2021
EPS came in at -$1.14 falling short of the estimated -$1.09 by -4.59%.
Earnings released on 5 Aug 2021
EPS came in at -$0.84 surpassing the estimated -$0.91 by +7.69%.
ARQT Stock Performance
Access detailed ARQT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
